EGF receptor as a therapeutic target

EGFR and Her-2 are overexpressed in lung cancers and have, therefore, been chosen as preferred targets for novel therapies. Recent results on Iressa trials show only a moderate response to the agent, even in cases where it is documented that EGFR is over-expressed. These findings prompted us to re-visit the oncogenic pathways, which play a rote in lung cancers, with special emphasis on the way EGFR/ Her-2 signaling cooperates with other signaling pathways. (C) 2003 Elsevier Science Ireland Ltd and Ainerican Society of Clinical Oncology. Published by Elsevier Science Ireland Ltd. All rights reserved.